Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer

  • Technology appraisal guidance
  • TA721
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence